James, Jehana <br/><br/>
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.  [electronic resource] 

 -  Investigational new drugs  Feb 2007 
 - 41-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0167-6997 
<br/><br/><label>Standard No.: </label>10.1007/s10637-006-9008-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Methoxyestradiol<br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Area Under Curve<br/>Breast Neoplasms--drug therapy<br/>Docetaxel<br/>Drug Administration Schedule<br/>Estradiol--adverse effects<br/>Fatigue--chemically induced<br/>Female<br/>Half-Life<br/>Humans<br/>Matrix Metalloproteinase 2--blood<br/>Matrix Metalloproteinase 9--blood<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Recurrence, Local<br/>Taxoids--adverse effects<br/>Treatment Outcome<br/>Tubulin Modulators--administration & dosage<br/>Urinalysis<br/>Vascular Cell Adhesion Molecule-1--blood<br/>Vascular Endothelial Growth Factor A--urine